Table 6.
Univariate analysis of the impact of p16 and pRB status in breast cancers on prognosis by the log-rank test
| Parameter | Number of patients/recurrence/death | Disease-free survival | Overall survival | ||
|---|---|---|---|---|---|
|
|
|
||||
| Mean survival (95% CI) months | P-value | Mean survival (95% CI) months | P-value | ||
| p16 | 0.279 | 0.369 | |||
| Negative | 31/5/5 | 95 (83-106) | 117 (102-132) | ||
| Positive | 375/36/38 | 126 (122-130) | 128 (124-131) | ||
| Alteration of p16 | 0.108 | 0.922 | |||
| No | 212/17/23 | 128 (123-133) | 128 (123-132) | ||
| Yes | 194/24/20 | 119 (113-125) | 125 (119-131) | ||
| pRB | 0.900 | 0.706 | |||
| Negative | 339/34/35 | 125 (121-130) | 127 (123-131) | ||
| Positive | 67/7/8 | 123 (115-131) | 123 (115-131) | ||
| p16/pRB status | n/a | 0.538 | |||
| p16(+)/pRB(+) | 64/7/7 | n/a | 124 (116-132) | ||
| p16(+)/pRB(-) | 311/29/31 | n/a | 127 (123-132) | ||
| p16(-)/pRB(+) | 3/0/1 | n/a | 94 (36-151) | ||
| p16(-)/pRB(-) | 28/5/4 | n/a | 119 (104-134) | ||
| Altered p16/ pRB status | 0.458 | 0.974 | |||
| Altered p16/pRB(+) | 31/4/4 | 120 (106-133) | 121 (108-133) | ||
| Altered p16/pRB(-) | 163/20/16 | 114 (108-120) | 125 (119-132) | ||
| Non-altered p16/pRB(+) | 36/3/4 | 111 (102-119) | 124 (114-135) | ||
| Non-altered p16/pRB(-) | 176/14 /19 | 128 (123-134) | 128 (122-133) | ||